12‐hydroxy‐eicosatetraenoic acid (12‐HETE): a biomarker of Churg‐Strauss syndrome

Authors:

Abstract
Summary: Background: Churg‐Strauss syndrome (CSS) shares similarities with asthma and hypereosinophilic syndrome (HES). Eicosanoids – important inflammatory and signaling molecules – are present in exhaled breath condensate (EBC) and broncho‐alveolar lavage fluid (BALF).Objectives: To assess eicosanoid profile both inEBCandBALFofCSSsubjects searching for a pattern characteristic of this syndrome.Methods: EBCs from 23CSSpatients, 30 asthmatics, 12HESpatients and 54 healthy controls (HC) were assessed quantitatively for 19 eicosanoids by a high‐performance liquid chromatography ‐ tandem mass spectrometry (HPLC‐MS/MS). In addition, in 21 of 23CSSsubjects and in nine asthmatics, eicosanoids were determined inBALF.Results: EBCfromCSSpatients showed markedly elevated levels of 12‐HETEas compared with other studied groups.BALFwas characterized by a significant elevation of 12‐HETEand its metabolite 12‐tetranorHETEinCSSas compared with asthma. Clinical activity ofCSScorrelated with 12‐HETEand its metabolites levels inBALF, but not inEBC.Conclusion and Clinical Relevance: CSSis clearly distinguished from bronchial asthma, andHESby a marked increase in 12‐HETEconcentration in bothEBCandBALF. This points to a possible new pathogenic mechanism inCSSand may help in future in establishing the diagnosis ofCSS.

This publication has 43 references indexed in Scilit: